AREDS Classification of Age-related Macular Degeneration
Age-Related Eye Disease Study simplified categories (AREDS Report 18, 2005). Stratifies risk of progression to advanced AMD over 5 years and guides AREDS2 supplementation.
Score interpretation
→ No supplementation indicated. Lifestyle: smoking cessation, Mediterranean diet, omega-3, UV protection.
→ Reassure; lifestyle measures. Self-monitoring with Amsler grid. AREDS2 supplements not generally indicated at this stage.
→ AREDS2 formula (lutein 10 mg, zeaxanthin 2 mg, vitamin C 500 mg, vitamin E 400 IU, zinc 80 mg, copper 2 mg) — reduces progression by ~25%. 6-monthly OCT and monitoring.
→ If neovascular: urgent intravitreal anti-VEGF (ranibizumab/aflibercept/faricimab) per NICE TA294/305/865. Geographic atrophy: low-vision rehab, pegcetacoplan/avacincaptad in selected systems. AREDS2 supplements for fellow eye protection.
Interpretation bands for the AREDS AMD. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Ranibizumab · Anti-VEGF (intravitreal injection)
- Bevacizumab (Intravitreal) · Anti-VEGF (Vascular Endothelial Growth Factor Inhibitor)
- Aflibercept 2mg/0.05mL Intravitreal Injection (Eylea) · Anti-VEGF agent (intravitreal)
- Faricimab (Intravitreal) · Anti-VEGF and Anti-Ang-2 — Bispecific Monoclonal Antibody
- Brolucizumab (Intravitreal) · Anti-VEGF — Single-chain Antibody Fragment (scFv)
- Pegaptanib Sodium · Anti-VEGF (RNA Aptamer) — Neovascular AMD
- Acute Red Eye / Vision Loss Screen · RCOphth 2020; NICE CKS
- Idiopathic Intracranial Hypertension · ABN; consensus 2018
- Acute Red Eye Assessment · RCOphth / AAO
- Acute Angle Closure Glaucoma · RCOphth / EGS Guidelines
- Retinal Detachment · RCOphth Guidelines / EURETINA
- Diabetic Retinopathy — Screening and Management · NICE NG28 2016 / NHS DES Programme
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.